Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc. has made significant strides in RNA editing technology, particularly with the unveiling of KRRO-121, a liver-targeted therapeutic that stabilizes glutamine synthetase (GS) and enhances ammonia clearance, addressing critical unmet medical needs in urea cycle disorders (UCD) and hepatic encephalopathy (HE) markets valued at approximately $1.5 billion and $2.0 billion, respectively. Robust preclinical data from animal models support KRRO-121’s efficacy in improving ammonia levels after challenges, which could lead to substantial pharmacoeconomic benefits by reducing hospitalizations and crises associated with these conditions. The company's strategic advancement towards an Investigational New Drug (IND) filing in the second half of 2026, accompanied by promising preclinical results demonstrating up to 40% editing efficiency, reinforces a positive outlook on its future growth and potential market impact.

Bears say

Korro Bio has experienced a negative stock performance, primarily due to disappointing results from its KRRO-110 program and the challenges associated with advancing its pipeline candidates, particularly KRRO-121, which introduces significant risks related to clinical trials. Additionally, the potential for unfavorable clinical outcomes and regulatory disagreements with the FDA and EMA heightens uncertainty around the company's future profitability and operational effectiveness. Furthermore, the threat of evolving competitive treatments and possible legal issues related to intellectual property could adversely impact Korro Bio's market position and financial stability.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.